Every 10-Q that Traws Pharma, Inc. (TRAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. reported no revenue for the three and six months ended June 30, 2026, down from $2.7 million and $2.8 million in the prior-year periods after termination of a Symbio license. The company recorded a six‑month net loss of $10.2 million versus prior‑year net income driven by a large 2025 warrant revaluation gain. Cash and cash equivalents were $5.0 million with total assets of $11.5 million and an accumulated deficit of $650.1 million.
Research and development expenses rose to $6.0 million for the first half of 2026, reflecting higher virology spending on tivoxavir marboxil and ratutrelvir, while general and administrative costs increased to $5.5 million, largely from higher professional fees and stock‑based compensation. A $1.4 million legacy R&D accrual reversal reduced operating expenses. Management states that current cash will not fund operations for 12 months, and explicitly notes substantial doubt about the ability to continue as a going concern.
Liquidity was supported by an April 2026 private placement providing $10.0 million in gross proceeds (about $9.4 million net) and ATM sales adding $2.0 million. New April 2026 warrants could provide up to $50.0 million in additional gross proceeds if fully exercised for cash. Clinically, ratutrelvir showed favorable Phase 2 COVID‑19 results, but tivoxavir marboxil faces an MHRA deferral for a human challenge study and a U.S. FDA clinical hold. Traws also received a Nasdaq notice for failing the $1.00 minimum bid price requirement.
Traws Pharma, Inc. reported a first-quarter 2026 net loss of $7.1 million, reversing net income a year earlier, as it ramped investment in its respiratory virus pipeline. Revenue was zero versus $57,000 in 2025, while research and development spending nearly doubled to $4.9 million, driven by work on ratutrelvir, tivoxavir marboxil and TRX01.
General and administrative costs fell to $2.0 million. Cash and cash equivalents were $3.1 million at March 31, 2026, against an accumulated deficit of $647.1 million and a working capital deficit of $7.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new capital.
In April 2026, Traws closed an equity financing with upfront gross proceeds of $10.0 million and issued milestone-based and common warrants that could raise up to an additional $50.0 million if fully exercised. The company also continued a legal arbitration with a former executive and detailed progress across its clinical programs, including Phase 2 development for ratutrelvir and ongoing regulatory interactions for tivoxavir marboxil.
Traws Pharma, Inc. reported Q3 results showing a net loss of $3.96 million as R&D and G&A totaled $2.31 million and $1.74 million, respectively. Cash and cash equivalents were $6.42 million at September 30, 2025, with total assets of $12.44 million. Stockholders’ equity improved to $4.55 million, aided by a sharp reduction in warrant liabilities.
For the nine months, the company recorded net income of $16.61 million, driven primarily by a $26.66 million non‑cash gain from the change in fair value and reclassification of warrant liabilities, and recognition of $2.79 million in revenue upon the termination of a legacy license. Operating cash outflow was $15.43 million year‑to‑date.
The company entered an ATM Agreement authorizing sales of up to $50 million in common stock and raised $3.27 million net by issuing 1,627,050 shares. It also acquired IP assets from Viriom for $2.35 million in cash, adding a patent now carried at $2.57 million. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern based on current cash projections.
Traws Pharma, Inc. completed an April 2024 asset acquisition of Trawsfynydd and now focuses on two lead antiviral programs, tivoxavir marboxil and ratutrelvir, while retaining oncology assets for potential partnerships. The asset acquisition included an in‑process R&D asset valued at $117.464 million.
For the three months ended June 30, 2025 the company reported $2.733 million of revenue and a net loss of $0.915 million; for the six months ended June 30, 2025 it reported $2.79 million of revenue and net income of $20.575 million, largely reflecting recognition of deferred revenue and significant changes and reclassifications of warrant liabilities. Cash and cash equivalents were $13.081 million at June 30, 2025 and the company stated it does not have sufficient cash to support operations for more than one year, noting substantial doubt about its ability to continue as a going concern. The company regained Nasdaq compliance with minimum stockholders’ equity and will be subject to a mandatory panel monitor for one year.